New York, January 10, 2026, 16:02 EST — Market closed
- Abbott said its FreeStyle Libre 3 Plus glucose sensor is now publicly funded across every province in Canada
- Shares ended down 0.2% on Friday, closing at $125.92
- Analysts raised and trimmed price targets ahead of Abbott’s Jan. 22 results
Abbott Laboratories (ABT) said its FreeStyle Libre 3 Plus glucose sensor is now publicly funded across every province in Canada. The stock ended down 0.2% at $125.92 on Friday.
The update lands with investors turning back to Abbott’s diabetes-device franchise heading into fourth-quarter results later this month. Abbott said it will report before the U.S. market opens on Jan. 22 and host a webcast that morning.
Analysts have started to revisit targets on large-cap healthcare names after a shaky 2025 run. Bernstein analyst Lee Hambright raised Abbott’s price target to $154 from $150 and kept an Outperform rating, TipRanks reported.
Goldman Sachs, meanwhile, lowered its price target on Abbott to $152 from $157 while keeping a Buy rating, TipRanks data showed. Goldman said its model does not include Abbott’s pending acquisition of Exact Sciences.
Abbott agreed in November to buy cancer test maker Exact Sciences in a deal valued at up to $23 billion including debt, its biggest deal in nearly a decade. The deal is expected to close in the second quarter of 2026, and Reuters reported it would be dilutive to Abbott’s adjusted earnings through 2027.
In Canada, Abbott said the Libre 3 Plus is now covered in federal plans such as Non‑Insured Health Benefits and by a majority of employer-sponsored workplace benefits programs. “Sensor-based glucose monitoring has transformed diabetes care,” said Akshay Jain, an endocrinologist in British Columbia, while Abbott’s Canada diabetes chief Luz Herrera called the broad coverage “a clear testament” to the technology’s impact. Newswire
Abbott has also been adding software around Libre. This week it unveiled Libre Assist, a feature in the Libre app that uses generative artificial intelligence — software that produces outputs based on patterns in data — to predict how a meal could affect glucose and suggest changes before a user eats. “People living with diabetes need more than apps that just log food,” said Marc Taub, a vice president in Abbott’s diabetes care business. Abbott MediaRoom
Friday’s slip left Abbott lagging a broader market rise into the weekend. The S&P 500 gained 0.65% on the day, while Danaher rose 1.43% and Johnson & Johnson fell 0.66%, MarketWatch data showed.
Abbott shares sit near the middle of their recent range. The stock’s 52-week range is $110.86 to $141.23, and its 50-day moving average is about $126, according to market data.
Wall Street expects Abbott to earn about $1.50 per share on roughly $11.8 billion in revenue for the quarter, according to MarketBeat’s compiled estimates. Traders will look for signs that devices can keep carrying the story, and whether management adds detail on the Exact Sciences timeline.
But the earnings setup is not clean. Abbott missed revenue estimates in October as diagnostics and nutrition weakness outweighed medical device strength, and the company pointed to volatility as it navigated pricing pressure in China and the drop in COVID-19 testing demand, Reuters reported.
Near-term dates stack up quickly. Abbott said its next quarterly dividend is 63 cents per share, payable Feb. 13 to shareholders of record on Jan. 15; U.S. consumer price data is due Jan. 13 and producer price data on Jan. 14. For Abbott shares, the next hard catalyst is the Jan. 22 earnings report before the bell.
